A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85

Radiotherapy and Oncology

Volumn 46, Issue 2, 1998, Pages 135-146

  Overgaard, Jens ^a   Hansen, Hanne Sand ^b   Overgaard, Marie ^a   Bastholt, Lars ^c   Berthelsen, Anne ^d   Specht, Lena ^d   Lindeløv, Birgit ^b   Jørgensen, Karsten ^c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b FINSEN LABORATORY   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Head and neck carcinoma; Hemoglobin; Nimorazole; Radiotherapy; Randomized clinical trial; Treatment related morbidity

Indexed keywords

NIMORAZOLE; PLACEBO;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED STUDY; DENMARK; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HEAD AND NECK CANCER; HUMAN; HYPOXIA; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PHARYNX CARCINOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOSENSITIZATION; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; CELL HYPOXIA; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; NIMORAZOLE; PHARYNGEAL NEOPLASMS; PLACEBOS; RADIATION-SENSITIZING AGENTS; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 0031909654     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(97)00220-X     Document Type: Article

References (47)

1. Ang, K.K. Accelerated fractionation: what is the price for speeding? Radiother. Oncol. 44: 97-99, 1997.
2. Bentzen, S.M. Towards evidence based radiation oncology: improving the design, analysis, and reporting of clinical outcome studies in radiotherapy. Radiother. Oncol. 46: 5-18, 1998.
3. Brizel, D., Sibley, G.S., Prosnitz, L.R., Scher, R.L. and Dewhirst, M.W. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 38: 285-289, 1997.
4. Brown, J.M. and Sum, B.G. Hypoxia-specific cytotoxins in cancer therapy. Semin. Radiat. Oncol. 6: 22-36, 1996.
5. Bush, R.S., Jenkin, R.D.T., Allt, W.E.C., Beale, F.A., Bean, H., Dembo, A.J. and Pringle, J.F. Definite evidence for hypoxic cells influencing cure in cancer therapy. Br. J. Cancer (Suppl. III): 302-306, 1978.
6. Chapman, J.D., Engelhardt, E.L., Stobbe, C.C., Schneider, R.F. and Hanks, G.E. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother. Oncol. 1998, in press.
7. Denekamp, J. and Fowler, J.F. ARCON - current status: summary of a workshop on preclinical and clinical studies. Acta Oncol. 36: 517-525, 1997.
8. Dische, S. Chemical sensitizers for hypoxic cells: a decade of experience in clinical radiotherapy. Radiother. Oncol. 3: 97-115, 1985.
9. Dische, S., Saunders, M., Barrett, A., Harvey, A., Gibson, D. and Parmar, M. A randomized multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother. Oncol. 44: 123-136, 1997.
10. EORTC Cooperative Group of Radiotherapy. Early results of the EORTC randomized clinical trial on multiple fractions per day (MFD) and misonidazole in advanced head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 12: 587-591, 1986.
11. Eschwege, F., Sancho-Garnier, H., Chassagne, D., Brisgand, D., Guerra, M., Malaise, E.P., Bey, P., Busutti, L., Cionini, L., N'Guyen, T., Romanini, A., Chauvaudra, J. and Hill, C. Results of a European randomized trial of etanidazole combined with radiotherapy in head and neck carcinomas. Int. J. Radiat. Oncol. Biol. Phys. 39: 275-281, 1997.
12. Fazekas, J., Pajak, T.F., Wasserman, T., Marcial, V., Davis, L., Kramer, S., Rotman, M. and Stetz, J. Failure of misonidazole-sensitized radiotherapy to impact upon outcome among stage III-IV squamous cancers of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 13: 1155-1160, 1987.
13. Fazekas, J.T., Scott, C., Marcial, V., Davis, L.W., Wasserman, T. and Cooper, J.S. The role of hemoglobin concentration in the outcome of misonidazole-sensitized radiotherapy of head and neck cancers: based on RTOG trial #79-15. Int. J. Radiat. Oncol. Biol. Phys. 17: 1177-1181, 1989.
14. Grau, C. and Overgaard, J. Significance of hemoglobin concentration for treatment outcome. In: Medical Radiology: Blood Perfusion and Microenvironment of Human Tumours, pp. 101-112. Editors: M. Molls and P. Vaupel. Springer-Verlag, Heidelberg, 1997.
15. Greenhalgh, T. Statistics for the non-statistician. II. 'Significant' relations and their pitfalls. Br. Med. J. 315: 422-425, 1997.
16. Haffty, B.G., Son, Y.H., Sasaki, C.T., Papac, R., Fischer, D., Rockwell, S., Sartorelli, A. and Fisher, J.J. Mitomycin C as an adjunct to postoperative radiation therapy in squamous cell carcinoma of the head and neck: results from two randomized clinical trials. Int. J. Radiat. Oncol. Biol. Phys. 27: 241-250, 1993.
17. Hansen, O., Overgaard, J., Hansen, H.S., Overgaard, M., Høyer, M., Jørgensen, K.E., Bastholt, L. and Berthelsen, A. Importance of overall treatment time for the outcome of radiotherapy of advanced head and neck carcinoma: dependency on tumor differentiation. Radiother. Oncol. 43: 47-51, 1997.
18. Henk, J.M., Kunkler, P.B. and Smith, C.W. Radiotherapy and hyperbaric oxygen in head and neck cancer. Final report of first controlled clinical trial. Lancet, ii: 101-103, 1977.
19. Henk, J.M. and Smith, C.W. Radiotherapy and hyperbaric oxygen in head and neck cancer. Interim report of second clinical trial. Lancet, ii: 104-105, 1977.
20. Hirst, D.G. Anemia: a problem or an opportunity in radiotherapy? Int. J. Radiat. Oncol. Biol. Phys. 12: 2009-2017, 1986.
21. Horiot, J.C., Bontemps, P., van den Bogaert, W., Le Fur, R., van den Weijngaert, D., Bolla, M., Bernier, J., Lusinchi, A., Stuschke, M., Lopez-Torrecilla, J., Begg, A.C., Pierart, M. and Colette, L. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother. Oncol. 44: 111-121, 1997.
22. Horsman, M.R. Nicotinamide and other benzamide analogs as agents for overcoming hypoxic cell radiation resistance in tumours. Acta Oncol. 34: 571-587, 1995.
23. Horwich, A., Holliday, S.B., Deacon, J.M. and Peckham, M.J. A toxicity and pharmakokinetic study in man of the hypoxic-cell radio-sensitiser RSU-1069. Br. J. Radiol. 59: 1238-1240, 1986.
24. Kaanders, J.H.A.M., Stratford, M.R.L., Liefers, J., Dennis, M.F., van der Kogel, A.J., van Daal, W.A.J. and Rojas, A. Administration of nicotinamide during a five-to-seven-week course of radiotherapy: pharmacokinetics, tolerance, and compliance. Radiother. Oncol. 43: 67-73, 1997.
25. Lee, D.-J., Cosmatos, D., Marcial, V.A., Fu, K., Rotman, M., Cooper, J.S., Ortiz, H.G., Beitler, J.J., Abrams, R.A., Curran, W.J., Coleman, C.N. and Wasserman, T.H. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole (SR-2508) with radiotherapy alone for locally advanced head and neck carcinomas. Int. J. Radiat. Oncol. Biol. Phys. 32: 567-576, 1995.
26. Lee, D.-J., Pajak, T.F., Stetz, J., Order, S.E., Weissberg, J.B. and Fischer, J.J. A phase III study of the hypoxic cell sensitizer misonidazole as an adjunct to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: a RTOG randomized study. Int. J. Radiat. Oncol. Biol. Phys. 16: 465-470, 1989.
27. MRC Working Party on Misonidazole in Head and Neck Cancer. A study of the effect of misonidazole in conjunction with radiotherapy for the treatment of head and neck cancer. Br. J. Radiol. 57: 585-595, 1984.
28. Nordsmark, M., Overgaard, M. and Overgaard, J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of head and neck. Radiother. Oncol. 41: 31-39, 1996.
29. Overgaard, J. The influence of hemoglobin concentration on the response to radiotherapy. Scand. J. Clin. Lab. Invest. 48 (Suppl. 189): 49-53, 1988.
30. Overgaard, J. Sensitization of hypoxic tumour cells - clinical experience. Int. J. Radiat. Biol. 56: 801-811, 1989.
31. Overgaard, J. Advances in clinical applications of radiobiology: phase III studies of radiosensitizers and novel fractionation schedules. In: Head and Neck Cancer, Vol. III, pp. 863-869. Editors: J.T. Johnson and M.S. Didolkar. Elsevier, Amsterdam, 1993.
32. Overgaard, J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol. Res. 6: 509-518, 1994.
33. Overgaard, J. Modification of hypoxia - from Gottwald Schwarz to nicotinamide. Have we learned the lesson? In: Progress in Radio-Oncology V, pp. 469-475. Editor: H.D. Kogelnik. Monduzzi Editore, Bologna, 1995.
34. Overgaard, J., Hansen, H.S., Andersen, A.P., Hjelm-Hansen, M., Jørgensen, K., Sandberg, E., Berthelsen, A., Hammer, R. and Pedersen, M. Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: report from the Dahanca 2 study. Int. J. Radiat. Oncol. Biol. Phys. 16: 1065-1068, 1989.
35. Overgaard, J., Hansen, H.S., Lindeløv, B., Overgaard, M., Jørgensen, K., Rasmusson, B. and Berthelsen, A. Nimorazole as a hypoxic radiosensitizer in the treatment of supraglottic larynx and pharynx carcinoma. First report from the Danish Head and Neck Cancer Study (DAHANCA) protocol 5-85. Radiother. Oncol. 20 (Suppl. 1): 143-149, 1991.
36. Overgaard, J., Hjelm-Hansen, M., Johansen, L.V. and Andersen, A.P. Comparison of conventional and split-course radiotherapy as primary treatment in carcinoma of the larynx. Acta Oncol. 27: 147-152, 1988.
37. Overgaard, J. and Horsman, M.R. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin. Radiat. Oncol. 6: 10-21, 1996.
38. Overgaard, J., Overgaard, M., Nielsen, O.S., Pedersen, A.K. and Timothy, A.R. A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo. Br. J. Cancer 46: 904-911, 1982.
39. Overgaard, J., Overgaard, M. and Timothy, A.R. Studies of the pharmacokinetic properties of nimorazole. Br. J. Cancer 48: 27-34, 1983.
40. Overgaard, J., Sand Hansen, H., Jørgensen, K. and Hjelm-Hansen, M. Primary radiotherapy of larynx and pharynx carcinoma. An ana-lysis of factors influencing local control and survival. Int. J. Radiat. Oncol. Biol. Phys. 12: 515-521, 1986.
41. Overgaard, J., Sand Hansen, H., Overgaard, M., Jørgensen, K., Bastholt, L., Berthelsen, A. and Pedersen, M. The Danish Head and Neck Cancer Study Group (DAHANCA) randomized trials with hypoxic radiosensitizers in carcinoma of the larynx and pharynx. In: Radiation Research. A Twentieth-Century Perspective, Vol. II, Congress Proceedings, pp. 573-577. Editors: W.C. Dewey, M. Edington, R.J.M. Fry, E.J. Hall and G.F. Whitmore. ICRR, Toronto, 1991.
42. Overgaard, J., Sand Hansen, H., Sapru, W., Overgaard, M., Grau, C., Jørgensen, K., Bastholt, L., Hansen, O., Specht, L., Berthelsen, A. and Pedersen, M. Conventional radiotherapy as the primary treatment of squamous cell carcinoma of the head and neck. A randomized multicenter study of 5 versus 6 fractions per week - preliminary report from the DAHANCA 6 and 7 trial. Radiother. Oncol. 40: S31, 1996.
43. Saunders, M.I., Hoskin, P.J., Pigott, K., Powell, M.E.B., Goodchild, K., Dische, S., Denekamp, J., Stratford, M.R.L., Dennis, M.F. and Rojas, A. Accelerated radiotherapy, carbogen and nicotinamide (ARCON) in locally advanced head and neck cancer: a feasibility study. Radiother. Oncol. 45: 159-166, 1997.
44. Sealy, R., Jacobs, P., Wood, L., Levin, W., Barry, L., Boniaszczuk, J. and Blekkenhorst, G. The treatment of tumours by the induction of anemia and irradiation in hyperbaric oxygen. Cancer 64: 646-652, 1989.
45. Stell, P.M. and Rawson, N.S.B. Adjuvant chemotherapy in head and neck cancer. Br. J. Cancer 61: 779-787, 1990.
46. Thrall, D.E., Rosner, G.L., Azuma, C., McEntee, M.C. and Raleigh, J.A. Hypoxia marker labeling in tumour biopsies: quantification of labeling variation and criteria for biopsy sectioning. Radiother. Oncol. 44: 171-176, 1997.
47. Timothy, A.R., Overgaard, J. and Overgaard, M. A phase I clinical study of nimorazole as a hypoxic radiosensitizer. Int. J. Radiat. Oncol. Biol. Phys. 10: 1765-1768, 1984.